Clinical Trial Update: Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1a/1b study of TPST-1495 as monotherapy and in combination with pembrolizumab has completed status, spanning multiple solid tumors including colorectal ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Endometrial Cancer
• Gastric Adenocarcinoma
• Gastroesophageal Junction Adenocarcinoma
• Non-small Cell Lung Cancer
• Pik3ca-mutant Solid Tumors
• Squamous Cell Carcinoma of the Head and Neck
• Urothelial Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• TPST-1495 (TPST-1495)

Snippet

Sponsor: Tempest Therapeutics | Conditions: Solid Tumor, Colorectal Cancer | Phase 1 | Status: COMPLETED